

MEDICINES NOTIFICATION

CLASS 4 MEDICINES DEFECT NOTIFICATION, EL(26)A/24

Caution In Use

Issued 14 May 2026

Distribute to Pharmacy/Wholesaler Level

MARKETING AUTHORISATION HOLDER (MAH)

Fresenius Medical Care Deutschland GmbH

MEDICINE DETAILS

balance 2.3% glucose, 1.25 mmol/l calcium, solution for peritoneal dialysis

PL: 13689/0013

Active Ingredient: In 1 litre ready-to-use solution:

Calcium chloride dihydrate	0.1838g
Sodium chloride	5.640g
Sodium (S) lactate solution (sodium (S) lactate)	7.85g (3.925g)
Magnesium chloride hexahydrate	0.1017g
Glucose monohydrate (anhydrous glucose)	25.0g (22.73g)

SNOMED code: N/A


GTIN: 4046241132298

AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
F4LM071	11/2026	2 x 5ltr bags	04/02/2025
G4LB133	01/2027	2 x 5ltr bags	01/07/2025
G4LL144	10/2027	2 x 5ltr bags	26/01/2026
G4LM152	11/2027	2 x 5ltr bags	23/02/2026
H4LB212	11/2028	2 x 5ltr bags	07/05/2026
G4LI151	08/2027	2 x 5ltr bags	26/01/2026

Background

Fresenius Medical Care Deutschland GmbH have identified an error in the Braille printed on the outer label. The Braille message on the balance 2.3% glucose, 1.25 mmol/l calcium, solution for peritoneal dialysis, incorrectly states ‘CAPD/DPCA 19’. All other label information and printed data are correct for all above listed batches.

Product	Issue
balance 2.3% glucose, 1.25 mmol/l calcium, solution for peritoneal dialysis	Braille message incorrectly states ‘CAPD/DPCA 19’
Correct Braille message balance 2.3% Glucose, 1.25 mmol/l calcium	
	

Advice for Healthcare Professionals:

There is no product quality issue, the affected batches will not be recalled. Where necessary, healthcare professionals should explain the Braille text error to patients who depend solely on braille for reading medicine packaging.

Advice for Healthcare Professionals to Provide to Patients:

Patients can continue using solution bags from the above batches, and no further action is required. Any required support or guidance will be provided by the relevant healthcare professionals.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

Additional information:

For all medical information enquiries and information on this product, please email Medinfo-UK@freseniusmedicalcare.com, or telephone 01623 445 215.

For stock control enquiries please email ukorders@freseniusmedicalcare.com, or telephone 01623 445 100.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to share this with Nephrologists & Renal Nurse practitioners for information.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU

Telephone +44 (0)20 3080 6574

DMRC@mhra.gov.uk